索格列净联合胰岛素治疗1型糖尿病成人患者的糖尿病酮症酸中毒及相关事件:inTandem 1和2研究的汇总分析
该分析汇总了两项设计相同的52周随机研究,评估索格列净联合胰岛素治疗1型糖尿病成人患者时糖尿病酮症酸中毒(DKA)及相关不良事件的发生率和危险因素。共有37起事件(36例患者)被裁定为DKA,安慰剂组、索格列净200 mg组和400 mg组的暴露调整发生率分别为每100患者年0.2、3.1和4.2起事件。实施风险缓解计划后,两个索格列净剂量组的DKA年化发生率均低于实施前,提示该风险可通过患者教育加以管理。
要点
- 索格列净联合胰岛素治疗会增加1型糖尿病患者的DKA发生率,且发生率随剂量升高。
- 索格列净组约47%和7%的患者分别出现至少1次β-羟丁酸(BHB)>0.6 mmol/L和>1.5 mmol/L,高于安慰剂组的20%和2%。
- 实施风险缓解计划后DKA发生率下降,提示患者教育有助于管理该风险。
核心结论
- 在1型糖尿病患者中,与单用胰岛素相比,加用索格列净后确诊DKA的发生率升高。
- 实施强化的风险缓解计划后观察到DKA发生率降低,提示该风险可通过患者教育加以管理。
研究设计与样本
- 汇总分析两项设计相同、为期52周的随机研究(inTandem 1和2),患者每日一次接受安慰剂、索格列净200 mg或索格列净400 mg。
- 分析DKA、β-羟丁酸(BHB)变化以及BHB>0.6 mmol/L和>1.5 mmol/L的患者百分比。
主要发现
- 共报告191起酮症相关不良事件,其中98起接受裁定;37起事件(36例患者)被裁定为DKA。
- DKA暴露调整发生率在安慰剂组、索格列净200 mg组和400 mg组分别为每100患者年0.2、3.1和4.2起事件。
- 无患者死于DKA事件。
- 从基线BHB约0.13 mmol/L起,索格列净治疗52周内中位增幅较小(所有时间点≤0.05 mmol/L)。
- 索格列净治疗患者中约47%和7%分别有至少1次BHB测量值>0.6 mmol/L和>1.5 mmol/L,安慰剂组分别为20%和2%。
关键数值与推荐
- DKA暴露调整发生率:安慰剂每100患者年0.2起,索格列净200 mg每100患者年3.1起,索格列净400 mg每100患者年4.2起。
- BHB>0.6 mmol/L的患者比例:索格列净组约47%,安慰剂组20%。
- BHB>1.5 mmol/L的患者比例:索格列净组约7%,安慰剂组2%。
- 基线BHB约0.13 mmol/L,索格列净治疗52周内中位增幅在所有时间点≤0.05 mmol/L。
临床怎么用
- 1型糖尿病患者加用索格列净时需警惕DKA风险,应开展患者教育并实施风险缓解计划。
- 治疗期间可关注BHB水平,BHB>0.6 mmol/L和>1.5 mmol/L的患者比例在索格列净组更高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the incidence and risk factors for diabetic ketoacidosis (DKA) and related adverse events (AEs) in adults with type 1 diabetes treated with sotagliflozin adjunctive to insulin. RESEARCH DESIGN AND METHODS: Data from two identically designed, 52-week, randomized studies were pooled and analyzed for DKA, changes in β-hydroxybutyrate (BHB), and percentage of patients with BHB >0.6 and >1.5 mmol/L. The patients were administered placebo, sotagliflozin 200 mg, or sotagliflozin 400 mg once daily. RESULTS: A total of 191 ketosis-related AEs were reported, and 98 underwent adjudication. Of these, 37 events (36 patients) were adjudicated as DKA, with an exposure-adjusted incidence rate of 0.2, 3.1, and 4.2 events per 100 patient-years for placebo, sotagliflozin 200 mg, and sotagliflozin 400 mg, respectively. No patient died of a DKA event. From a baseline BHB of ∼0.13 mmol/L, sotagliflozin treatment led to a small median increase over 52 weeks (≤0.05 mmol/L at all time points). Of sotagliflozin-treated patients, approximately 47% and 7% had ≥1 BHB measurement >0.6 mmol/L and >1.5 mmol/L, respectively (vs. 20% and 2%, respectively, of placebo-treated patients). Subsequent to the implementation of a risk mitigation plan, annualized DKA incidence was lower versus preimplementation in both the sotagliflozin 200 and 400 mg groups. CONCLUSIONS: In patients with type 1 diabetes, confirmed DKA incidence increased when sotagliflozin was added to insulin compared with insulin alone. A lower incidence of DKA was observed following the implementation of an enhanced risk mitigation plan, suggesting that this risk can be managed with patient education.
引用
- Peters AL, McGuire DK, Danne T, et al. Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies. Diabetes Care. 2020. PMID: 32928957. doi:10.2337/dc20-0924
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。